Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 39,903 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 39,903 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $30.48, for a total transaction of $1,216,243.44. Following the completion of the transaction, the chief financial officer directly owned 60,609 shares of the company’s stock, valued at approximately $1,847,362.32. This represents a 39.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.04, for a total transaction of $1,045,662.36.
• On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.60, for a total transaction of $146,512.80.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $30.61 on Friday. The stock’s 50-day moving average is $26.64 and its 200 day moving average is $23.79. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $31.04. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The firm had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. On average, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Sei Investments Co. raised its stake in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the period. Bank of New York Mellon Corp lifted its holdings in Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after purchasing an additional 22,471 shares in the last quarter. Corient Private Wealth LP lifted its stake in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC bought a new position in shares of Kestra Medical Technologies in the first quarter worth about $603,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KMTS. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective on the stock. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.00.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.